Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 7/20 | 0.45 |
| ▸ | NOS2 | P35228 | 4/20 | 0.45 |
| ▸ | KCNH3 | Q9ULD8 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 3/20 | 0.42 |
| ▸ | APP | P05067 | 1/20 | 0.42 |
| ▸ | NOS1 | P29475 | 10/20 | 0.42 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19143346 | 0.89 | ASIC3 (0.44) | NOS3NOS2KCNH3BACE1APP | |
| SCHEMBL523614 | 0.84 | NPSR1 (0.54) | CXCR4NPSR1 | |
| SCHEMBL18465500 | 0.83 | KCNH3 (0.45) | NOS3NOS2KCNH3BACE1APP | |
| SCHEMBL31338416 | 0.81 | KCNH3 (0.44) | NOS3NOS2KCNH3BACE1APP | |
| SCHEMBL1075990 | 0.80 | CXCR4 (0.43) | NOS3NOS2KCNH3BACE1APP | |
| Hydrochloric Acid SCHEMBL31338408 | 0.79 | KCNH3 (0.47) | NOS3NOS2KCNH3BACE1APP | |
| SCHEMBL8986161 | 0.79 | NPSR1 (0.46) | NOS2NOS1CXCR4NPSR1 | |
| SCHEMBL2476858 | 0.77 | SMN1; SMN2 (0.53) | NOS3NOS2CXCR4NPSR1ADORA2A | |
| SCHEMBL7333040 | 0.77 | CXCR4 (0.52) | CXCR4NPSR1 | |
| SCHEMBL29791992 | 0.77 | SMN1; SMN2 (0.53) | NOS3NOS2CXCR4NPSR1ADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023109120-A1 | TYK2 INHIBITORS AND COMPOSITIONS AND METHODS THEREOF | LYNK PHARMACEUTICALS CO. LTD. (CN) | 2023-06-22 | — | — | WO | disclosed |
| WO-2020035052-A1 | PYRAZINE COMPOUNDS AND USES THEREOF | DIZAL (JIANGSU) PHARMACEUTICAL CO., LTD. (CN) | 2020-02-20 | — | — | WO | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | ASTELLAS PHARMA INC. (JP) | 2008-09-18 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-7375222-B2 | 2,4,6-Triamino-1,3,5-triazine derivative | ASTELLAS PHARMA INC. (JP) | 2008-05-20 | — | — | US | disclosed |
| US-20010034445-A1 | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORPORATION | 2001-10-25 | — | — | US | disclosed |
| EP-0895475-A4 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORP (US) | 2000-08-23 | — | — | EP | disclosed |
| CN-1209060-A | Vitronectin receptor antagonists | SMITHKLINE BEECHAM CORP (US) | 1999-02-24 | — | — | CN | disclosed |
| EP-0895475-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-02-10 | — | — | EP | disclosed |
| WO-1997024122-A1 | VITRONECTIN RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1997-07-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034445-A1 | Vitronectin receptor antagonists | ADGRF1, GPR174, CALCRL | NOS3 2385/4885NOS2 2809/4885KCNH3 3137/4885 |
| US-20080227785-A1 | 2,4,6-TRIAMINO-1,3,5-TRIAZINE DERIVATIVE | KCNT1, KCNMA1, KCNJ2 | NOS3 1722/4885NOS2 1948/4885KCNH3 47/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.